Prows Lab

Publications

Trivedi, VS; Magnusen, AF; Rani, R; Marsili, L; Slavotinek, AM; Prows, DR; Hopkin, RJ; McKay, MA; Pandey, MK. Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy. International Journal of Molecular Sciences. 2022; 23:14340.

Bein, K; Ganguly, K; Martin, TM; Concel, VJ; Brant, KA; Peter Di, YP; Upadhyay, S; Fabisiak, JP; Vuga, LJ; Kaminski, N; et al. Genetic determinants of ammonia-induced acute lung injury in mice. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2021; 320:L41-L62.

Zimmermann, N; Jr, GW J; Homan, SM; Prows, DR. Heart disease in a mutant mouse model of spontaneous eosinophilic myocarditis maps to three loci. BMC Genomics. 2019; 20:727.

Snedeker, J; Jr, GW J; Paulding, DF; Abdelhamed, Z; Prows, DR; Stottmann, RW. Gpr63 is a modifier of microcephaly in Ttc21b mouse mutants. Editor, Cox GA. PLoS Genetics. 2019; 15:e1008467.

Prows, DR; Klingler, A; Jr, GW J; Homan, SM; Zimmermann, N. Characterization of a mouse model of hypereosinophilia-associated heart disease. American Journal of Physiology: Heart and Circulatory Physiology. 2019; 317:H405-H414.